Neuroptika

Neuroptika is a private, preclinical biotech developing innovative treatments for retinal diseases, primarily glaucoma and age-related macular degeneration (AMD). The company's pipeline includes two lead programs: NRO-CMK, a neuroprotective gene therapy for glaucoma targeting retinal ganglion cells, and NRO-VTN, an antibody-based therapy aimed at inhibiting drusen formation in dry AMD. Founded in 2019 and led by a co-CEO team with expertise in science/IP and corporate finance, the company is positioned to address the growing global patient population with significant unmet medical needs. Neuroptika is currently in the preclinical research and development phase.

Dual-modality approach utilizing AAV-based gene therapy for neuroprotection (targeting intracellular pathways like CaMKII) and antibody-based biologics for targeting extracellular pathology (e.g., vitronectin in drusen). Focus on intravitreal delivery for targeted retinal intervention.

The competitive landscape is intense. In dry AMD, numerous companies are pursuing diverse approaches (complement inhibition, neuroprotection, gene therapy), with several in late-stage trials. The glaucoma neuroprotection space is also active, though with a history of clinical failures, creating a high bar for success. Neuroptika's niche focus on specific targets (CaMKII, vitronectin) differentiates it but remains unproven.